Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.

Oncogene - 25 Sept 1997

Hui R, Campbell D H, Lee C S, McCaul K, Horsfall D J, Musgrove E A, Daly R J, Seshadri R, Sutherland R L

Abstract excerpt

Chromosome 11q13 is amplified in about 13% of primary breast cancers. CCND1, encoding the cell cycle regulatory gene cyclin D1, and EMS1, encoding a filamentous actin binding protein, are favoured candidate onocogenes, whereas INT-2 is an unexpressed gene at this locus. In this study we tested the possibility that different regions of this large amplicon could be independently amplified and subsequently defined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Chromosomes, Human, Pair 11

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Genetic Markers

Share to Microfilament Proteins

Share to Neoplasm Proteins

Share to Phenotype

Share to Proto-Oncogene Proteins

Source

Identifiers

PMID: 9380415
DOI: 10.1038/sj.onc.1201311

Genes

CCND1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer.PMID 9380415Read ↗

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.Semantic proximity Read ↗

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.Semantic proximity Read ↗

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assaysSemantic proximity Read ↗

Functional characterization of EMSY gene amplification in human cancersSemantic proximity Read ↗

Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinomaSemantic proximity Read ↗

PPFIA1 and CCND1 are frequently coamplified in breast cancer.Semantic proximity Read ↗

Prognostic Relevance of Gene Amplifications and Coamplifications in Breast CancerSemantic proximity Read ↗

Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancerSemantic proximity Read ↗

EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survivalSemantic proximity Read ↗

High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer.Semantic proximity Read ↗

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.Semantic proximity Read ↗

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.